Zentalis Pharmaceuticals’ (ZNTL) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) in a research note issued to investors on Monday,Benzinga reports. They currently have a $10.00 price objective on the stock.

Several other brokerages also recently issued reports on ZNTL. UBS Group reduced their price target on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Wedbush restated a “neutral” rating and set a $4.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday, January 24th. Finally, Wells Fargo & Company lowered their price objective on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a report on Thursday, January 30th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Zentalis Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $8.24.

Zentalis Pharmaceuticals Price Performance

Shares of Zentalis Pharmaceuticals stock opened at $1.79 on Monday. The firm has a market capitalization of $127.56 million, a PE ratio of -0.72 and a beta of 1.75. The company’s fifty day moving average price is $2.14 and its two-hundred day moving average price is $2.92. Zentalis Pharmaceuticals has a 52-week low of $1.61 and a 52-week high of $16.27.

Insider Activity at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, insider Ingmar Bruns purchased 20,000 shares of the stock in a transaction on Thursday, February 6th. The shares were purchased at an average price of $2.28 per share, with a total value of $45,600.00. Following the acquisition, the insider now directly owns 36,629 shares in the company, valued at approximately $83,514.12. The trade was a 120.27 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jan Skvarka acquired 60,000 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were purchased at an average cost of $1.72 per share, for a total transaction of $103,200.00. Following the completion of the acquisition, the director now owns 149,551 shares in the company, valued at $257,227.72. This represents a 67.00 % increase in their position. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

A number of large investors have recently bought and sold shares of ZNTL. Erste Asset Management GmbH bought a new stake in shares of Zentalis Pharmaceuticals during the third quarter valued at approximately $37,000. Paloma Partners Management Co bought a new stake in Zentalis Pharmaceuticals in the third quarter worth $37,000. Corton Capital Inc. purchased a new position in shares of Zentalis Pharmaceuticals in the fourth quarter worth $32,000. Captrust Financial Advisors purchased a new position in shares of Zentalis Pharmaceuticals in the fourth quarter worth $33,000. Finally, Aigen Investment Management LP purchased a new position in shares of Zentalis Pharmaceuticals in the third quarter worth $41,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.